-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] The Science and Technology Innovation Board has a high degree of tolerance for biotechnology companies.
The fifth set of listing criteria is: the estimated market value is not less than 4 billion yuan, and pharmaceutical industry companies need to have at least one core product approved for Phase II clinical trials test
etc.
This set of listing standards has attracted many IPOs of Biotech companies that have not yet made a profit because there are no requirements for the company's operating income and net profit
.
The data shows that as of August 31, 18 innovative pharmaceutical companies have passed the fifth set of criteria to land on the Science and Technology Innovation Board
.
At present, listed companies have basically disclosed their 2022 interim reports.
So, how did these pharmaceutical companies perform in the first half of the year? According to statistics, among the 18 companies that have disclosed their mid-year reports, nearly 80% of Biotech still continues to lose money, including Zejing Pharmaceutical, Junshi Bio, Shenzhou Cell, Dizhe Medicine, etc.
However, CanSino, Alys, Olin The four companies of Biotechnology and Shanghai Yizhong have turned losses into profits
.
Among them, CanSino will turn losses into profits in 2021 driven by vaccine products.
In the first half of 2022, the company achieved operating income of about 630 million yuan, a decrease of 69.
45% over the same period of the previous year; The net profit was RMB 12.
238 million, a decrease of 98.
69% over the same period of the previous year
.
As for the reasons for the sharp decline in performance, CanSino attributed it to the decrease in demand for vaccines and the price adjustment of vaccine products
.
According to the semi-annual report, CanSino is an innovative vaccine company dedicated to R&D, production and commercialization that meets Chinese and international standards
.
In March 2009, the company was listed on the H-shares of the main board of the Hong Kong Stock Exchange.
In August 2020, it landed on the Science and Technology Innovation Board, becoming the first "A+H" vaccine stock since the opening of the Science and Technology Innovation Board
.
Alice Alice’s 2022 semi-annual report shows that during the reporting period, it achieved an operating income of 300 million yuan, a year-on-year increase of 147.
34%, a net profit of 26.
7645 million yuan, a year-on-year turnaround from a loss to a profit, and a loss of 78.
3418 million yuan in the same period last year
.
It is reported that in the first half of the year, the company's sales volume of fumetinib has driven the company's performance to achieve a significant year-on-year increase
.
Fumetinib is the company's core product, a class I new drug independently developed by the company, which is mainly aimed at the treatment of patients with EGFR-mutant non-small cell lung cancer
.
The announcement shows that the company's second-line treatment indications for fumetinib have been approved for marketing in March 2021, and it was included in the national medical insurance list that year, and the product has been in high volume
.
In addition, the first-line treatment indication was approved in June 2022, and it is expected to participate in the medical insurance negotiation this year.
The company stated that the application for the first-line treatment indication to enter the national medical insurance catalogue is in an orderly progress
.
According to another announcement, fumetinib for the treatment of NSCLC with exon 20 insertion mutation has been included in the list of breakthrough therapy varieties in May 2022, and was approved to conduct phase II clinical trials in China in August; The indications for adjuvant therapy of tinib have also entered the phase III clinical trial stage
.
In addition, the company has also established a preparation production workshop that meets the requirements of GMP, which provides sufficient production capacity for fumetinib, and also accumulates kinetic energy for the supply of the company's subsequent pipeline products
.
According to the data, Ailes was established on March 22, 2004.
The company's main business is the research and development, production and sales of innovative drugs in the field of tumor treatment
.
On December 2, 2020, Alice officially landed on the Science and Technology Innovation Board
.
Olin Bio The 2022 semi-annual report released by Olin Bio shows that the company achieved operating income of 233 million yuan, a year-on-year increase of 37.
60%, and a net profit of 31.
0424 million yuan, a year-on-year decrease of 26.
71%
.
It is reported that the company's revenue in the first half of this year maintained a double-digit growth rate, which was mainly due to the increase in sales revenue of the core products adsorbed tetanus vaccine and Hib vaccine
.
According to the data, Olin Bio was listed on the Science and Technology Innovation Board on June 8, 2021
.
The company is a biopharmaceutical enterprise focusing on the research, development, production and sales of human vaccines.
The products currently on the market include adsorbed tetanus vaccine, Hib conjugate vaccine and AC conjugate vaccine
.
Among them, the adsorbed tetanus vaccine was the first product launched by Olin Bio in June 2017
.
Shanghai Yizhong Shanghai Yizhong achieved operating income of 71.
8708 million yuan in the first half of this year; net profit of 60.
9792 million yuan, turning losses into profits year-on-year
.
The company explained that the reason for the increase in revenue was that the company's products were not listed in the same period last year, and no operating income was realized
.
After paclitaxel micelles were approved for listing in October 2021, the company started commercial production and sales.
Sales increased in the first half of this year, driving revenue growth
.
According to the data, on September 9, 2021, Shanghai Yizhong was listed on the Science and Technology Innovation Board
.
The company is committed to the R&D and industrialization of new improved anti-tumor drugs, and its core product is paclitaxel polymer micelles for injection
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
The fifth set of listing criteria is: the estimated market value is not less than 4 billion yuan, and pharmaceutical industry companies need to have at least one core product approved for Phase II clinical trials test
etc.
This set of listing standards has attracted many IPOs of Biotech companies that have not yet made a profit because there are no requirements for the company's operating income and net profit
.
The data shows that as of August 31, 18 innovative pharmaceutical companies have passed the fifth set of criteria to land on the Science and Technology Innovation Board
.
At present, listed companies have basically disclosed their 2022 interim reports.
So, how did these pharmaceutical companies perform in the first half of the year? According to statistics, among the 18 companies that have disclosed their mid-year reports, nearly 80% of Biotech still continues to lose money, including Zejing Pharmaceutical, Junshi Bio, Shenzhou Cell, Dizhe Medicine, etc.
However, CanSino, Alys, Olin The four companies of Biotechnology and Shanghai Yizhong have turned losses into profits
.
Among them, CanSino will turn losses into profits in 2021 driven by vaccine products.
In the first half of 2022, the company achieved operating income of about 630 million yuan, a decrease of 69.
45% over the same period of the previous year; The net profit was RMB 12.
238 million, a decrease of 98.
69% over the same period of the previous year
.
As for the reasons for the sharp decline in performance, CanSino attributed it to the decrease in demand for vaccines and the price adjustment of vaccine products
.
According to the semi-annual report, CanSino is an innovative vaccine company dedicated to R&D, production and commercialization that meets Chinese and international standards
.
In March 2009, the company was listed on the H-shares of the main board of the Hong Kong Stock Exchange.
In August 2020, it landed on the Science and Technology Innovation Board, becoming the first "A+H" vaccine stock since the opening of the Science and Technology Innovation Board
.
Alice Alice’s 2022 semi-annual report shows that during the reporting period, it achieved an operating income of 300 million yuan, a year-on-year increase of 147.
34%, a net profit of 26.
7645 million yuan, a year-on-year turnaround from a loss to a profit, and a loss of 78.
3418 million yuan in the same period last year
.
It is reported that in the first half of the year, the company's sales volume of fumetinib has driven the company's performance to achieve a significant year-on-year increase
.
Fumetinib is the company's core product, a class I new drug independently developed by the company, which is mainly aimed at the treatment of patients with EGFR-mutant non-small cell lung cancer
.
The announcement shows that the company's second-line treatment indications for fumetinib have been approved for marketing in March 2021, and it was included in the national medical insurance list that year, and the product has been in high volume
.
In addition, the first-line treatment indication was approved in June 2022, and it is expected to participate in the medical insurance negotiation this year.
The company stated that the application for the first-line treatment indication to enter the national medical insurance catalogue is in an orderly progress
.
According to another announcement, fumetinib for the treatment of NSCLC with exon 20 insertion mutation has been included in the list of breakthrough therapy varieties in May 2022, and was approved to conduct phase II clinical trials in China in August; The indications for adjuvant therapy of tinib have also entered the phase III clinical trial stage
.
In addition, the company has also established a preparation production workshop that meets the requirements of GMP, which provides sufficient production capacity for fumetinib, and also accumulates kinetic energy for the supply of the company's subsequent pipeline products
.
According to the data, Ailes was established on March 22, 2004.
The company's main business is the research and development, production and sales of innovative drugs in the field of tumor treatment
.
On December 2, 2020, Alice officially landed on the Science and Technology Innovation Board
.
Olin Bio The 2022 semi-annual report released by Olin Bio shows that the company achieved operating income of 233 million yuan, a year-on-year increase of 37.
60%, and a net profit of 31.
0424 million yuan, a year-on-year decrease of 26.
71%
.
It is reported that the company's revenue in the first half of this year maintained a double-digit growth rate, which was mainly due to the increase in sales revenue of the core products adsorbed tetanus vaccine and Hib vaccine
.
According to the data, Olin Bio was listed on the Science and Technology Innovation Board on June 8, 2021
.
The company is a biopharmaceutical enterprise focusing on the research, development, production and sales of human vaccines.
The products currently on the market include adsorbed tetanus vaccine, Hib conjugate vaccine and AC conjugate vaccine
.
Among them, the adsorbed tetanus vaccine was the first product launched by Olin Bio in June 2017
.
Shanghai Yizhong Shanghai Yizhong achieved operating income of 71.
8708 million yuan in the first half of this year; net profit of 60.
9792 million yuan, turning losses into profits year-on-year
.
The company explained that the reason for the increase in revenue was that the company's products were not listed in the same period last year, and no operating income was realized
.
After paclitaxel micelles were approved for listing in October 2021, the company started commercial production and sales.
Sales increased in the first half of this year, driving revenue growth
.
According to the data, on September 9, 2021, Shanghai Yizhong was listed on the Science and Technology Innovation Board
.
The company is committed to the R&D and industrialization of new improved anti-tumor drugs, and its core product is paclitaxel polymer micelles for injection
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
